CAR-T cell therapy company Poseida is seeking to raise $115m in an initial public offering (IPO), according to papers filed with securities regulators. Poseida Therapeutics, which is testing CAR-T cell therapies for blood-borne and solid tumour cancers, has filed for a Nasdaq listing under the symbol PSTX. The company wants to use any IPO proceedings to further fund clinical development and research of its CAR-T treatment for relapsed/refractory multiple myeloma. It may also set up a pilot manufacturing unit, with an estimated cost of up to $15m, the filing showed.
CAR-T cell therapy company Poseida Therapeutics is seeking to raise $115m in an initial public offering (IPO), according to papers filed with securities regulators. Poseida, which is testing CAR-T cell therapies for blood-borne and solid tumour cancers, has filed for a Nasdaq listing under the symbol PSTX. The company wants to use any IPO proceedings to further fund clinical development and research of its CAR-T treatment for relapsed/refractory multiple myeloma. It may also set up a pilot manufacturing unit, with an estimated cost of up to $15m, the filing showed.